Oxford vaccine team wins £1.4m to develop jab against ‘super gonorrhoea’
30 March 2021
The Oxford University institute behind the AstraZeneca Covid vaccine has been awarded $2 million (£1.4m) to develop a jab against the increasing threat of “super gonorrhoea”.
Researchers at the Jenner Institute believe their vaccine, one of just a handful currently in development, will prevent infections from different strains of the sexually transmitted infection (STI), including the most powerful multi-drug resistant forms that are spreading around the world.
Further reading: The Telegraph
Author(s): Anne Gulland
Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support kindly provided by
 |
Antimicrobial Resistance Fighter Coalition |
 |
CDD VAULT Complexity Simplified |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
